Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
Explore this paper's citation graph
Summary
The generation of clinical grade CAR(+) T cells is an example of bench-to-bedside translational science that has been accomplished using investigator-initiated trials operating largely without industry support, and the next-generation trials will deliver designer T cells with improved homing, CAR-mediated signaling, and replicative potential, as investigators move from the bedside to the bench and back again.
- Type
- review
- Published
- 2010-08-19
- Cited by
- 323
- References
- 170
- Access
- Open access
- OpenAlex
- https://openalex.org/W2004919491
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:422133
Keywords
Chimeric antigen receptor, Homing (biology), Reprogramming, Immunotherapy, Clinical trial
References
- Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
- IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells
- Structure-based prediction of insertion-site preferences of transposons into chromosomes
- Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
- The T-body approach: redirecting T cells with antibody specificity.
- Are we nearly there yet
- Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation
- Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation
- Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
- Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.
- Tumor-Derived Chemokine MCP-1/CCL2 Is Sufficient for Mediating Tumor Tropism of Adoptively Transferred T Cells1
- Functional Human Antigen-Specific T Cells Produced In Vitro Using Retroviral T Cell Receptor Transfer into Hematopoietic Progenitors1
- A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity
- Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
- Genetic engineering of T cell specificity for immunotherapy of cancer.
- An entirely humanized CD3 ζ‐chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen–positive tumor cells
- Highly efficient redirected anti‐tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor
- Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased anti-leukemic efficacy in vivo
- Comparison of Common γ-Chain Cytokines, Interleukin-2, Interleukin-7, and Interleukin-15 for the In Vitro Generation of Human Tumor-Reactive T Lymphocytes for Adoptive Cell Transfer Therapy
- Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.
Cited by
- Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM
- Adoptive cell transfer: new perspective treatment in veterinary oncology
- CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered NK Cells and T Cells Enhance In Vitro and In Vivo Anti-Tumor Activity Against Human Multiple Myeloma
- Engineered cell-based therapies: a vanguard of design-driven medicine.
- CAR-MODIFIED T CELLS CAPABLE OF DISTINGUISHING NORMAL CELLS FROM MALIGNANT CELLS
- T-CELL TREATMENTS FOR SOLID AND HEMATOLOGICAL TUMORS
- CD56-SPECIFIC T CELLS: USING GENETICALLY ENGINEERED T CELLS TO REDIRECT SPECIFICITY TO A T CELL EXPRESSED ANTIGEN
- Transposable elements in cancer and other human diseases.
- IL-21 is not necessary for anti-lymphoma effects of T cells expressing second-generation CD19-specific chimeric antigen receptors in a xenograft mouse model.
- [New immunotherapeutic approaches in oncology and hematology].
- Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations
- SELECTION METHODS FOR GENETICALLY-MODIFIED T CELLS: IN SUPPORT OF TRANSLATIONAL THERAPY
- The Dynamics of Interactions Among Immune and Glioblastoma Cells
- Evaluation and optimization of immunomagnetic methods for the purification and selection of CMV-specific cytotoxic T lymphocytes from G-CSF primed peripheral blood mononuclear cells for adoptive immunotherapy
- T‐cell receptor retrogenic mice: a rapid, flexible alternative to T‐cell receptor transgenic mice
- ROR1-a Novel Receptor Tyrosine Kinase with Unique Therapeutic Potentials in Chronic Lymphocytic Leukemia
- Desarrollo de nuevas estrategias de inmunoterapia antitumoral basadas en la secreción in vivo de anticuerpos biespecíficos
- Engineering human pluripotent stem cells for enhanced lymphocyte development and function
- Challenges in T cell receptor gene therapy
- T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo
Related papers
- [The translational medicine approach to acupuncture and moxibustion].
- Tumor treatment based on translational medicine
- Preserving a legacy for our patients: The bedside-to-bench award in translational research
- The "Excellence in Translational Medicine" and "Bedside-to-Bench" Awards 2008-09
- [Strengthen researches on translational medicine and regenerative medicine in burns].
- International Journal of Translational Medicine: An Interdisciplinary Open Access Journal to Publish Your Biomedical Research with a “Bench-to-Bedside” Approach